This Day On The Street
Continue to site right-arrow
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Stocks Under $10 with 50-100% upside potential - 14 days FREE!

Telik Announces Phase 1 Results Of A Multicenter Study Of Telintra® (Ezatiostat Hydrochloride, TLK199) In Combination With Revlimid® (Lenalidomide) In Patients With Myelodysplastic Syndrome

Stocks in this article: TELK

PALO ALTO, Calif., Dec. 13, 2011 /PRNewswire/ -- Telik, Inc. (Nasdaq: TELK) today announced positive results from a Phase 1 multicenter dose-ranging trial of the combination of Telintra and Revlimid in patients with International Prognostic System Score (IPSS) Low to Intermediate-1 Risk non-deletion (5q) myelodysplastic syndrome (MDS).  

The majority of MDS patients are Low to Intermediate-1 Risk non-deletion (5q) and represent an important unmet medical need.  Although Revlimid currently is not approved for the treatment of non-deletion (5q) MDS it is used in this setting because of limited alternatives.  The rationale for the combination of Telintra and Revlimid is based on Telintra's novel mechanism of action, lack of suppression of white blood cell levels and the efficacy seen in single-agent Phase 1 and Phase 2 studies in the Low to Intermediate-1 Risk non-deletion (5q) MDS patient population.

The primary objective of the study was to establish the safety of the combination and the optimal dosing for Telintra in combination with the standard dose of Revlimid.  The secondary objectives were to assess the efficacy as measured by rates of hematologic improvement in red blood cell, white blood cell and platelet levels, and decreases in blood transfusions, according to International Working Group criteria (IWG 2006).  

Nineteen patients were treated at 9 investigational centers.  Patients received Telintra at a starting dose of 2000 mg in combination with standard dose Revlimid (10 mg) on days 1-21 of a 28-day cycle.  In stage 1, 3-6 patients in a standard 3+3 design were treated before escalation to the 2500 mg Telintra and 10 mg Revlimid dose levels.  The optimal dose of the combination was 2000 mg Telintra and 10 mg of Revlimid.  This cohort was expanded by an additional 10 patients in stage 2.

The median age was 75 years, with 5 patients having IPSS Low Risk classification and 14 patients having Intermediate-1 Risk.  Thirteen of 19 patients (68%) were red blood cell transfusion-dependent and required a median of 6 units of blood (range 4-10) during an 8 week period.  Two patients were platelet transfusion-dependent and 4 additional patients (21%) had clinically-significant low platelet levels.  

1 of 4

Select the service that is right for you!

Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!


DOW 17,804.80 +26.65 0.15%
S&P 500 2,070.65 +9.42 0.46%
NASDAQ 4,765.38 +16.9840 0.36%

Brokerage Partners

Rates from

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs